Anti-EGFR Monoclonal Antibodies in the First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The PEAK Experience
In this podcast, I will discuss first-line usage of anti-EGFR therapies in metastatic colorectal cancer in the context of the PEAK trial findings with a focus on the emerging data surrounding RAS oncogene mutations in treatment selection.